Investigational drug · Phase 2
SYN-004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "SYN-004"
First trial start
2021
Feb 15, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYN-004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
- Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "SYN-004" as an intervention, largest first.
- A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTIPivotal-lookingCompleted
Theriva Biologics, Inc.Industry
NCT02563106 · 413 participants · Start Oct 2015 · Primary completion Nov 2016
Drug: SYN-004; Placebo · For: Clostridium Difficile; Clostridium Infections
Sites: Little Rock, Arkansas; Torrance, California; DeLand, Florida · 43 sites in all
- SYN-004 Safety and Tolerability in Allo-HCT SubjectsActive, not recruiting
Theriva Biologics, Inc.Industry
NCT04692181 · 36 participants (planned) · Start Feb 15, 2021 · Primary completion Sep 30, 2029
Drug: SYN-004, Ribaxamase or Placebo · For: Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Sites: St Louis, Missouri
Synermore Biologics Co., Ltd.Industry
NCT04363242 · 22 participants · Start Apr 9, 2020 · Primary completion Jul 31, 2023
Drug: SYN125; SYN004 · For: Epithelial Carcinoma; Solid Tumor
Sites: Fairway, Kansas; Brownstown, Michigan; St Louis, Missouri · 4 sites in all
Theriva Biologics, Inc.Industry
NCT02473640 · 15 participants · Start Jun 2015 · Primary completion Apr 2016
Drug: SYN-004; Esomeprazole and 1 more · For: Healthy Volunteers With Ileostomy
Sites: Edmonton, Canada; Montreal, Canada
Theriva Biologics, Inc.Industry
NCT02419001 · 11 participants · Start Mar 2015 · Primary completion Sep 2015
Drug: Period 1 - Treatment Sequence AB; Period 1 - Treatment Sequence AC and 2 more · For: Healthy Volunteers
Sites: Columbus, Ohio; Edmonton, Canada; Montreal, Canada
Synermore Biologics Co., Ltd.Industry
NCT02391727 · 10 participants · Start May 2015 · Primary completion Oct 2018
Drug: SYN004 · For: Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Sites: New Orleans, Louisiana; St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- Early-life antibiotic exposures: Paving the pathway for dysbiosis-induced disorders.
Attiq A · Eur J Pharmacol 2025
- The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects.
Alshrari AS, Hudu SA, Elmigdadi F, et al. · Biomedicines 2023
- SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
Connelly S, Fanelli B, Hasan NA, et al. · Microorganisms 2020
- Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.
Connelly S, Fanelli B, Hasan NA, et al. · AIMS Public Health 2019
- The current novel therapeutic regimens for Clostridium difficile infection (CDI) and the potentials of Traditional Chinese Medicine in treatment of CDI.
Gao Y, Li H, Yang H, et al. · Crit Rev Microbiol 2019
- Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.
Connelly S, Fanelli B, Hasan NA, et al. · Microorganisms 2019
Also in development for Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
- RibaxamasePhase 21 trial
Theriva Biologics, Inc. · Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.